Mutations in the Nrf2 gene in the Keap1 interaction domain, resulting in loss of Keap1 binding and consequent increase of Nrf2-mediated response, were found in several tumours including non-small cell lung cancer (NSCLC), hepatocarcinoma (HCC), multiple myeloma (MM), head and neck carcinoma (HNC), oesophagal carcinoma (ESC), bladder cancer (BC) [66,67]. This evidence concerns the gene KEAP1 and urinary bladder carcinoma.